Market Analysis and Insights: Global Relapsing Multiple Sclerosis Treatment Market
The research report studies the Relapsing Multiple Sclerosis Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Relapsing Multiple Sclerosis Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Relapsing Multiple Sclerosis Treatment Scope and Segment
The global Relapsing Multiple Sclerosis Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Relapsing Multiple Sclerosis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Immunomodulatory
Immunosuppressive
Interferons
Others
by Sales Channel, this report covers the following segments
Hospital Pharmacy
Retail Pharmacy
Online Stores
Global Relapsing Multiple Sclerosis Treatment market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Relapsing Multiple Sclerosis Treatment key players in this market include:
Pfizer
Merck & Co
Teva Pharmaceutical
Sanofi
Bayer
Biogen
Roche
Novartis
CinnaGen
Mylan
Bristol-Myers Squibb
Janssen Pharmaceuticals
Acorda Therapeutics
The research report studies the Relapsing Multiple Sclerosis Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Relapsing Multiple Sclerosis Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Relapsing Multiple Sclerosis Treatment Scope and Segment
The global Relapsing Multiple Sclerosis Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Relapsing Multiple Sclerosis Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Immunomodulatory
Immunosuppressive
Interferons
Others
by Sales Channel, this report covers the following segments
Hospital Pharmacy
Retail Pharmacy
Online Stores
Global Relapsing Multiple Sclerosis Treatment market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Relapsing Multiple Sclerosis Treatment key players in this market include:
Pfizer
Merck & Co
Teva Pharmaceutical
Sanofi
Bayer
Biogen
Roche
Novartis
CinnaGen
Mylan
Bristol-Myers Squibb
Janssen Pharmaceuticals
Acorda Therapeutics
1 Market Overview of Relapsing Multiple Sclerosis Treatment
1.1 Relapsing Multiple Sclerosis Treatment Market Overview
1.1.1 Relapsing Multiple Sclerosis Treatment Product Scope
1.1.2 Relapsing Multiple Sclerosis Treatment Market Status and Outlook
1.2 Global Relapsing Multiple Sclerosis Treatment Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Relapsing Multiple Sclerosis Treatment Market Size by Region (2016-2027)
1.4 Global Relapsing Multiple Sclerosis Treatment Historic Market Size by Region (2016-2021)
1.5 Global Relapsing Multiple Sclerosis Treatment Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Relapsing Multiple Sclerosis Treatment Market Size (2016-2027)
1.6.1 North America Relapsing Multiple Sclerosis Treatment Market Size (2016-2027)
1.6.2 Europe Relapsing Multiple Sclerosis Treatment Market Size (2016-2027)
1.6.3 Asia-Pacific Relapsing Multiple Sclerosis Treatment Market Size (2016-2027)
1.6.4 Latin America Relapsing Multiple Sclerosis Treatment Market Size (2016-2027)
1.6.5 Middle East & Africa Relapsing Multiple Sclerosis Treatment Market Size (2016-2027)
2 Relapsing Multiple Sclerosis Treatment Market Overview by Type
2.1 Global Relapsing Multiple Sclerosis Treatment Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Relapsing Multiple Sclerosis Treatment Historic Market Size by Type (2016-2021)
2.3 Global Relapsing Multiple Sclerosis Treatment Forecasted Market Size by Type (2022-2027)
2.4 Immunomodulatory
2.5 Immunosuppressive
2.6 Interferons
2.7 Others
3 Relapsing Multiple Sclerosis Treatment Market Overview by Sales Channel
3.1 Global Relapsing Multiple Sclerosis Treatment Market Size by Sales Channel: 2016 VS 2021 VS 2027
3.2 Global Relapsing Multiple Sclerosis Treatment Historic Market Size by Sales Channel (2016-2021)
3.3 Global Relapsing Multiple Sclerosis Treatment Forecasted Market Size by Sales Channel (2022-2027)
3.4 Hospital Pharmacy
3.5 Retail Pharmacy
3.6 Online Stores
4 Relapsing Multiple Sclerosis Treatment Competition Analysis by Players
4.1 Global Relapsing Multiple Sclerosis Treatment Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Relapsing Multiple Sclerosis Treatment as of 2020)
4.3 Date of Key Players Enter into Relapsing Multiple Sclerosis Treatment Market
4.4 Global Top Players Relapsing Multiple Sclerosis Treatment Headquarters and Area Served
4.5 Key Players Relapsing Multiple Sclerosis Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Relapsing Multiple Sclerosis Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.1.4 Pfizer Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.1.5 Pfizer Recent Developments
5.2 Merck & Co
5.2.1 Merck & Co Profile
5.2.2 Merck & Co Main Business
5.2.3 Merck & Co Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.2.4 Merck & Co Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.2.5 Merck & Co Recent Developments
5.3 Teva Pharmaceutical
5.3.1 Teva Pharmaceutical Profile
5.3.2 Teva Pharmaceutical Main Business
5.3.3 Teva Pharmaceutical Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.3.4 Teva Pharmaceutical Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.4.4 Sanofi Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.4.5 Sanofi Recent Developments
5.5 Bayer
5.5.1 Bayer Profile
5.5.2 Bayer Main Business
5.5.3 Bayer Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.5.4 Bayer Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.5.5 Bayer Recent Developments
5.6 Biogen
5.6.1 Biogen Profile
5.6.2 Biogen Main Business
5.6.3 Biogen Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.6.4 Biogen Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.6.5 Biogen Recent Developments
5.7 Roche
5.7.1 Roche Profile
5.7.2 Roche Main Business
5.7.3 Roche Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.7.4 Roche Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.7.5 Roche Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.8.4 Novartis Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.8.5 Novartis Recent Developments
5.9 CinnaGen
5.9.1 CinnaGen Profile
5.9.2 CinnaGen Main Business
5.9.3 CinnaGen Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.9.4 CinnaGen Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.9.5 CinnaGen Recent Developments
5.10 Mylan
5.10.1 Mylan Profile
5.10.2 Mylan Main Business
5.10.3 Mylan Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.10.4 Mylan Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.10.5 Mylan Recent Developments
5.11 Bristol-Myers Squibb
5.11.1 Bristol-Myers Squibb Profile
5.11.2 Bristol-Myers Squibb Main Business
5.11.3 Bristol-Myers Squibb Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.11.4 Bristol-Myers Squibb Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.11.5 Bristol-Myers Squibb Recent Developments
5.12 Janssen Pharmaceuticals
5.12.1 Janssen Pharmaceuticals Profile
5.12.2 Janssen Pharmaceuticals Main Business
5.12.3 Janssen Pharmaceuticals Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.12.4 Janssen Pharmaceuticals Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.12.5 Janssen Pharmaceuticals Recent Developments
5.13 Acorda Therapeutics
5.13.1 Acorda Therapeutics Profile
5.13.2 Acorda Therapeutics Main Business
5.13.3 Acorda Therapeutics Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.13.4 Acorda Therapeutics Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.13.5 Acorda Therapeutics Recent Developments
6 North America
6.1 North America Relapsing Multiple Sclerosis Treatment Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Relapsing Multiple Sclerosis Treatment Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Relapsing Multiple Sclerosis Treatment Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Relapsing Multiple Sclerosis Treatment Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Relapsing Multiple Sclerosis Treatment Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Relapsing Multiple Sclerosis Treatment Market Dynamics
11.1 Relapsing Multiple Sclerosis Treatment Industry Trends
11.2 Relapsing Multiple Sclerosis Treatment Market Drivers
11.3 Relapsing Multiple Sclerosis Treatment Market Challenges
11.4 Relapsing Multiple Sclerosis Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
1.1 Relapsing Multiple Sclerosis Treatment Market Overview
1.1.1 Relapsing Multiple Sclerosis Treatment Product Scope
1.1.2 Relapsing Multiple Sclerosis Treatment Market Status and Outlook
1.2 Global Relapsing Multiple Sclerosis Treatment Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Relapsing Multiple Sclerosis Treatment Market Size by Region (2016-2027)
1.4 Global Relapsing Multiple Sclerosis Treatment Historic Market Size by Region (2016-2021)
1.5 Global Relapsing Multiple Sclerosis Treatment Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Relapsing Multiple Sclerosis Treatment Market Size (2016-2027)
1.6.1 North America Relapsing Multiple Sclerosis Treatment Market Size (2016-2027)
1.6.2 Europe Relapsing Multiple Sclerosis Treatment Market Size (2016-2027)
1.6.3 Asia-Pacific Relapsing Multiple Sclerosis Treatment Market Size (2016-2027)
1.6.4 Latin America Relapsing Multiple Sclerosis Treatment Market Size (2016-2027)
1.6.5 Middle East & Africa Relapsing Multiple Sclerosis Treatment Market Size (2016-2027)
2 Relapsing Multiple Sclerosis Treatment Market Overview by Type
2.1 Global Relapsing Multiple Sclerosis Treatment Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Relapsing Multiple Sclerosis Treatment Historic Market Size by Type (2016-2021)
2.3 Global Relapsing Multiple Sclerosis Treatment Forecasted Market Size by Type (2022-2027)
2.4 Immunomodulatory
2.5 Immunosuppressive
2.6 Interferons
2.7 Others
3 Relapsing Multiple Sclerosis Treatment Market Overview by Sales Channel
3.1 Global Relapsing Multiple Sclerosis Treatment Market Size by Sales Channel: 2016 VS 2021 VS 2027
3.2 Global Relapsing Multiple Sclerosis Treatment Historic Market Size by Sales Channel (2016-2021)
3.3 Global Relapsing Multiple Sclerosis Treatment Forecasted Market Size by Sales Channel (2022-2027)
3.4 Hospital Pharmacy
3.5 Retail Pharmacy
3.6 Online Stores
4 Relapsing Multiple Sclerosis Treatment Competition Analysis by Players
4.1 Global Relapsing Multiple Sclerosis Treatment Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Relapsing Multiple Sclerosis Treatment as of 2020)
4.3 Date of Key Players Enter into Relapsing Multiple Sclerosis Treatment Market
4.4 Global Top Players Relapsing Multiple Sclerosis Treatment Headquarters and Area Served
4.5 Key Players Relapsing Multiple Sclerosis Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Relapsing Multiple Sclerosis Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.1.4 Pfizer Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.1.5 Pfizer Recent Developments
5.2 Merck & Co
5.2.1 Merck & Co Profile
5.2.2 Merck & Co Main Business
5.2.3 Merck & Co Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.2.4 Merck & Co Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.2.5 Merck & Co Recent Developments
5.3 Teva Pharmaceutical
5.3.1 Teva Pharmaceutical Profile
5.3.2 Teva Pharmaceutical Main Business
5.3.3 Teva Pharmaceutical Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.3.4 Teva Pharmaceutical Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.3.5 Sanofi Recent Developments
5.4 Sanofi
5.4.1 Sanofi Profile
5.4.2 Sanofi Main Business
5.4.3 Sanofi Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.4.4 Sanofi Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.4.5 Sanofi Recent Developments
5.5 Bayer
5.5.1 Bayer Profile
5.5.2 Bayer Main Business
5.5.3 Bayer Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.5.4 Bayer Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.5.5 Bayer Recent Developments
5.6 Biogen
5.6.1 Biogen Profile
5.6.2 Biogen Main Business
5.6.3 Biogen Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.6.4 Biogen Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.6.5 Biogen Recent Developments
5.7 Roche
5.7.1 Roche Profile
5.7.2 Roche Main Business
5.7.3 Roche Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.7.4 Roche Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.7.5 Roche Recent Developments
5.8 Novartis
5.8.1 Novartis Profile
5.8.2 Novartis Main Business
5.8.3 Novartis Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.8.4 Novartis Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.8.5 Novartis Recent Developments
5.9 CinnaGen
5.9.1 CinnaGen Profile
5.9.2 CinnaGen Main Business
5.9.3 CinnaGen Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.9.4 CinnaGen Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.9.5 CinnaGen Recent Developments
5.10 Mylan
5.10.1 Mylan Profile
5.10.2 Mylan Main Business
5.10.3 Mylan Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.10.4 Mylan Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.10.5 Mylan Recent Developments
5.11 Bristol-Myers Squibb
5.11.1 Bristol-Myers Squibb Profile
5.11.2 Bristol-Myers Squibb Main Business
5.11.3 Bristol-Myers Squibb Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.11.4 Bristol-Myers Squibb Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.11.5 Bristol-Myers Squibb Recent Developments
5.12 Janssen Pharmaceuticals
5.12.1 Janssen Pharmaceuticals Profile
5.12.2 Janssen Pharmaceuticals Main Business
5.12.3 Janssen Pharmaceuticals Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.12.4 Janssen Pharmaceuticals Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.12.5 Janssen Pharmaceuticals Recent Developments
5.13 Acorda Therapeutics
5.13.1 Acorda Therapeutics Profile
5.13.2 Acorda Therapeutics Main Business
5.13.3 Acorda Therapeutics Relapsing Multiple Sclerosis Treatment Products, Services and Solutions
5.13.4 Acorda Therapeutics Relapsing Multiple Sclerosis Treatment Revenue (US$ Million) & (2016-2021)
5.13.5 Acorda Therapeutics Recent Developments
6 North America
6.1 North America Relapsing Multiple Sclerosis Treatment Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Relapsing Multiple Sclerosis Treatment Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Relapsing Multiple Sclerosis Treatment Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Relapsing Multiple Sclerosis Treatment Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Relapsing Multiple Sclerosis Treatment Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Relapsing Multiple Sclerosis Treatment Market Dynamics
11.1 Relapsing Multiple Sclerosis Treatment Industry Trends
11.2 Relapsing Multiple Sclerosis Treatment Market Drivers
11.3 Relapsing Multiple Sclerosis Treatment Market Challenges
11.4 Relapsing Multiple Sclerosis Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
